Academy
Intracerebral transplantation of autologous adipose‐derived stem cells for chronic ischemic stroke: A phase I study (2021)
GXNPC1® has demonstrated significant neurological improvement in patients with chronic stroke. The Phase I Clinical results showed an improvement of 5–15 points on the NIHSS, an increase of 25–50 points on the Barthel Index, and MRI scans indicated a reduction in infarcted brain regions. No safety concerns were observed during a 6-month follow-up period.
Chiu, T. L., Baskaran, R., Tsai, S. T., Huang, C. Y., Chuang, M. H., Syu, W. S., Harn, H. J., Lin, Y. C., Chen, C. H., Huang, P. C., Wang, Y. F., Chuang, C. H., Lin, P. C., & Lin, S. Z. (2022). Intracerebral transplantation of autologous adipose-derived stem cells for chronic ischemic stroke: A phase I study. Journal of tissue engineering and regenerative medicine, 16(1), 3–13.
Therapeutic Effect of Ligustilide-Stimulated Adipose-Derived Stem Cells in a Mouse Thromboembolic Stroke Model (2016)
The adipose-derived stem cells (ADSCs) pretreated with Ligustilide increases the expression levels of homing factors such as SDF-1 and CXCR4; the preconditioned ADSCs also demonstrated better therapeutic effects in a mouse thromboembolic stroke compared to Naïve ADSCs.
Chi, K., Fu, R. H., Huang, Y. C., Chen, S. Y., Lin, S. Z., Huang, P. C., Lin, P. C., Chang, F. K., & Liu, S. P. (2016). Therapeutic Effect of Ligustilide-Stimulated Adipose-Derived Stem Cells in a Mouse Thromboembolic Stroke Model. Cell transplantation, 25(5), 899–912.
The Use of ADSCs as a Treatment for Chronic Stroke (2014)
Treatment with adipose-derived stem cells (ADSCs) demonstrated therapeutic potential in restoring neurological function in stroke animal models, offering a safe and promising pathway for clinical application.
Chan, T. M., Harn, H. J., Lin, H. P., Chiu, S. C., Lin, P. C., Wang, H. I., Ho, L. I., Chuu, C. P., Chiou, T. W., Hsieh, A. C., Chen, Y. W., Ho, W. Y., & Lin, S. Z. (2014). The use of ADSCs as a treatment for chronic stroke. Cell transplantation, 23(4-5), 541–547.